

DRAFT AGENDA

7th MASCC/ISOO Mucositis Research Workshop

26 June 2014, 7.30 am to 11.30 am.

Miami Convention Center, Room A101/102, Miami, USA.

7.30. Light Breakfast

8.00. Call to Order and Welcome: Dr. Rajesh V. Lalla, Workshop Chair.

8:10 to 9:40 **Session 1: Pre-clinical studies**

Session Chair: Dr. Dorothy Keefe

8:10 to 9:40: 6 proffered papers 15 min each (10 min presentation + 5 min questions and discussion)

8.10: Serum-derived immunoglobulin shows early promise in the alleviation of irinotecan-induced mucositis

E. Bateman, E. Weaver, G. Klein, E. Plews, A. Wignall, B. Wozniak, and D. Keefe*

University of Adelaide, Adelaide, SA, Australia

8.25: Treatment of experimental irinotecan induced mucositis with GLP-1 and GLP-2

Hannelouise Kissow, Emilie Balk-Møller, Bolette Hartmann*

University of Copenhagen, Copenhagen, Denmark

8.40: The new selective GLP-2 receptor agonist, Elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat.

B. Mayo, E. Bateman, A. Stringer, E. Plews, A. Wignall, B. Wozniak, I. White, C. Pietra, S. Cantoreggi and D. Keefe*

University of Adelaide and University of South Australia, Adelaide, SA, Australia

8.55: Complete suppression of oral mucositis in preclinical animal models using topically applied vasoconstrictor (and its use in an upcoming study in bone marrow transplant patients)

Margo L. Hoover-Regan, Amanda J. Graul-Conroy, Kenneth B. DeSantes, Walter L. Longo, Paul M.

*Sondel and William E. Fahl**

University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

9.10: Gastrointestinal mucositis is associated with Muc 2 and 4 expression, and exocytosis of mucin stores.

Daniel Thorpe Ross Butler, Masooma Sultani, Andrea Stringer*

University of South Australia, Adelaide, SA, Australia

9.25: Does TLR4/PKC signalling drive chemotherapy induced barrier dysfunction and mucositis? (Research Proposal)

Hannah R Wardill, Rachel J Gibson, Richard M Logan, and Joanne M Bowen.*

University of Adelaide, Adelaide, SA, Australia

9.40 to 10.00: BREAK

10.00 to 11:00: Session 2: Clinical Studies

Session Chair: Dr. Michael Brennan

10.00 to 11.00: 4 proffered papers 15 min each (10 min presentation + 5 min questions and discussion)

10:00: Low level laser treatment for the management of oral mucositis: mechanisms of action, irradiation parameters and dose

Carroll J, Barasch A, Dominguez JA, Epstein JB, Nair RG, Raber-Durlacher JE, Bensadoun RJ.*
Griffith University, Southport, Queensland, Australia

10.15: Analgesic opioid therapy for oral mucositis associated pain during curative chemoradiotherapy in oropharyngeal cancer patients

Paolo Bossi, Roberta Granata, Salvatore Alfieri, Carla Ripamonti, Laura Locati, Cristiana Bergamini, Martina Imbimbo, Carlo Resteghini, Ester Orlandi, Carlo Fallai, Lisa Licitra.*
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

10.30: Oral mucositis related to radiotherapy for head and neck: evaluation of the effectiveness of a new anti-inflammatory product (Mucosyte®).

R.Di Franco, Matteo Muto, V.Ravo, D.Borrelli, A.Pepe, S.Falivene, A.Argenone, G.Guida, P.Muto*
Emicenter (European Medical Imaging Center), Casavatore, NA, Italy

10:45: Role of salivary dysfunction in hematopoietic stem cell transplant patients: OraStem Study

I. von Bültzingslöwen, P.M. Williams, F. Samim, P. Johansson, K. Garming Legert, B. Hasséus, Jan-Erik Johansson, M.T. Brennan*
Sahlgrenska Academy, Göteborg, Sweden

11:00 to 11:30: Expert Panel Discussion

Expert Panel Members: Drs. Michael Brennan, Dorothy Keefe, and Ourania Nicolatou-Galitis
Moderator: Dr. Sharon Elad, Workshop Co-Chair

11.30: Adjourn.

Disclaimer: The mention of any product or therapeutic modality does not imply its endorsement by the Mucositis Study Group, MASCC or ISOO.